Phylogenetic analysis of the cytochrome P450 (CYP450) nucleotide sequences of the horse and predicted CYP450s of the white rhinoceros (*Ceratotherium simum*) and other mammalian species

Marion Leiberich[1], Hendrik Johannes Marais[2] and Vinny Naidoo[3]

[1] Department of Companion Animal Clinical Studies, Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa
[2] Saving the Survivors, Pretoria, South Africa
[3] Department of Paraclinical Science, Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa

Corresponding author
Marion Leiberich,
u13404106@tuks.co.za

ABSTRACT

Background: The plight of the white rhinoceros (*Ceratotherium simum*) and the increasing need of treatment options for injured poaching victims led to the necessity to expand the knowledge on applicable drugs in this endangered species. With very little information available on drug pharmacokinetics in rhino, veterinarians have to rely on information generated from other species. The horse being a closely related species, has served as the model for dose extrapolations. However, from recent research on enrofloxacin and carprofen, the white rhino showed considerable differences in the pharmacokinetic properties of these drugs in comparison to the horse. While the reason for the differences is unknown, a likely cause may be a difference in present cytochrome P450 (CYP450), which may result in the rhino being genetically deficient in certain enzyme families.

Methods: For this paper we assess the degree of similarity of the CYP genome sequences across the different species, using BLAT (BLAST-like alignment tool) for the alignment of the nucleotide sequences of the equine CYP450 with potential homologous nucleotide sequences of the published database from white rhinos and other mammalian species (cow, pig, dog, sheep, elephant, mouse and human).

Results: The white rhino nucleotide sequences were 90.74% identical to the equine sequences. This was higher than the degree of similarity between any of the other evaluated species sequences. While no specific CYP family were found to be deficient in the published rhino genome, the horse genome contained additional genetic sequence for a larger number of iso-enzymes that were not present in the rhino.

Discussion: In pharmacokinetic study, it is well known that absence of a metabolic enzyme will result in constraints in drug metabolism and drug elimination. While this was our speculation, comparison to the horse and other mammalian species indicate that all the described CYP genes required for metabolism are present within the rhino genome. These results leave functional differences in enzyme activity and a lack of isoenzymes as the likely reason for the constraint in drug

metabolism. Despite a more than 90% similarity of the equine and rhino gene sequences, seemingly small differences can have major effects on drug metabolism. Thus, in spite of the close anatomical relationship, the rhino should not simply be treated like a big horse.

INTRODUCTION

The brutal poaching crisis which led to the killing of thousands of rhinos over the last few years (*Poaching Statistics, 2018*; *Emslie et al., 2016*) has drawn special attention to the plight of this threatened species. With the increasing number of rhinos requiring urgent medical help, the need to optimise the treatment of severely injured poaching victims is substantial. Unfortunately, with the need of appropriate drugs being a relatively recent problem, scientifically evaluated data for the treatment of rhino is lacking. Furthermore, research in wildlife medicine is often complicated by the animals' size and untamed nature, by the lack of sufficient numbers of study animals, and is often challenging due to their status as endangered species.

As a result, wildlife veterinarians have resorted to using the horse (*Equus caballus*) as a model for the treatment of white rhino (*Ceratotherium simum*). While from a general phylogenetic point of view the horse is regarded as one of the closest related species to the rhinoceros (*Tougard et al., 2001*), we questioned whether it is correct to treat rhinos like large horses. Studies (*Leiberich et al., 2018*; M. Leiberich, 2018, unpublished data) have recently been undertaken in order to elucidate this issue. Enrofloxacin and carprofen, two potential drugs for the antimicrobial and analgesic treatment of poaching victims and other injured white rhinos, were evaluated in plasma pharmacokinetic studies. These studies revealed significant differences between drug pharmacokinetic parameters in the white rhino and the horse. Carprofen was characterised by a half-life of elimination of 105.71 ± 15.67 h, which is by far the longest recorded for any animal species (*Leiberich et al., 2018*). Furthermore, interspecies allometric scaling of enrofloxacin was able to show that the difference in the half-life of enrofloxacin in white rhino was not only due to the relative differences in their body size and that the half-life was not allometrically scalable (M. Leiberich, 2018, unpublished data). Overall, these studies suggest that the white rhino is a slow metaboliser of some drugs and that the rhino is not simply comparable with the horse. While speculative, it was believed that the interspecies differences result at least partially from differences in drug metabolising enzymes and possibly from a lack of an important drug metabolising enzyme family. However, very little is known about the metabolic capacity of different animal species and about the causes of variation in drug metabolism. Consequently, the assessment of the drug metabolising units is needed.

The most important drug metabolising enzymes are the cytochrome P450s (CYP450), a diverse family of heme containing monooxygenases (*Ioannides, 2006*;

Toutain, Ferran & Bousquet-Mélou, 2010), which play a major role in phase I reactions (*Smith, 2009*). The discovery of CYP450 enzymes dates back to the 1950s, when Klingenberg first described the carbon monoxide binding pigment with its absorbance maximum around 450 nm (*Estabrook, 2003*; *Klingenberg, 1958*). Already in the 1960s, the CYP450s were known to be linked to the drug and steroid metabolism (*Nebert & Russell, 2002*). Nowadays, the diverse functions have been further elucidated and range from the synthesis of steroid hormones (*Payne & Hales, 2004*) and endogenous epithelial relaxation factor (*Fisslthaler et al., 1999*) to the metabolism of xenobiotics (*Anzenbacher & Anzenbacherova, 2001*). For classification purposes, the CYP450 enzymes have been divided into families sharing a primary structure, which is at least 40% identical. The classification into subfamilies, characterised by letters, is based on a more than 55% identical primary structure (*Van Der Weide & Hinrichs, 2006*). The individual isoenzymes differ by a minimum of 3% and are characterised by a second arabic number at the end (*Anzenbacher & Anzenbacherova, 2001*; *Nelson, 2006*). The major CYP450 families involved in drug metabolism are the CYP1, CYP2 and CYP3 families which account for more than 90% of the drug oxidation in humans (*Ioannides, 2006*; *Zanger & Schwab, 2013*). While cytochrome P450 enzymes have been widely studied in humans, information for animal species is scarce (*Fink-Gremmels, 2008*). Despite the interest in adequate animal models for human drug development and the interest in the prediction of drug residue levels in production animal species, the scientific knowledge in this field is still in its infancy (*Fink-Gremmels, 2008*; *Ioannides, 2006*; *Martignoni, Groothuis & De Kanter, 2006*).

The aim of this study was to assess the degree of in silico similarity between the CYP enzyme sequences published for the horse and other mammalian species with the rhino. The main objective was to ascertain if the rhino could be genetically deficient in any particular CYP enzyme families, which would provide insight for observed prominent differences in drug metabolism. The phylogenetic relationship of the CYP enzymes of the horse and the gene sequence of selected species including the white rhino, the cow (*Bos taurus*), the dog (*Canis lupus familiaris*), the pig (*Sus scrofa*), the elephant (*Loxodanta africana*), the sheep (*Ovis aries*), the mouse (*Mus musculus*) and the human (*Homo sapiens*) was assessed.

MATERIALS AND METHODS

A data mining strategy was applied to match the cytochrome P450 gene sequences of the horse to the gene sequences of selected species (Table 1) in order to determine the existence and the degree of homologous sequences amongst the different species. Fifteen identified CYP genes of the horse, namely CYP11A1, CYP17A1, CYP19A1, CYP27B1, CYP2A13, CYP2C113, CYP2C92, CYP2D50, CYP2E1, CYP3A89, CYP3A93, CYP3A94, CYP3A95, CYP3A96 and CYP3A97 (*Wade et al., 2009*) were used to perform a BLAT (BLAST like alignment tool) (*Kent, 2002*) search against the NCBI genome assemblies for the selected species (*Archibald et al., 2010a*, *2010b*; *Jiang et al., 2014*; *Lindblad-Toh et al., 2005*; *Uenishi et al., 2012*; *Zimin et al., 2009*). Sequences with less than 15% alignment were taken out automatically. Using the Molecular Evolutionary Genetics Analysis

Table 1 Selected species, corresponding accession ID numbers and additional sample information included in the comparison to the gene sequences of CYP enzymes.

Species	Accession ID	Additional sample information
Horse (*Equus caballus*)	GCA_000002305.1	Female, thoroughbred, isolate Twilight
White rhinoceros (*Ceratotherium simum*)	GCA_000283155.1	Female
Cow (*Bos taurus*)	GCA_000003055.4	Pooled male and female samples, Hereford, tissue blood
Dog (*Canis lupus familiaris*)	GCA_000002285.2	Female Boxer
Pig (*Sus scrofa domesticus*)	GCA_000003025.4	Female, Duroc, isolate TL Tabasco
Elephant (*Loxodonta africana*)	GCA_000001905.1	Female
Sheep (*Ovis aries*)	GCA_000298735.1	Male and female, Texel
Mouse (*Mus musculus*)	GCA_000001305.2	Strain C57BL/6J
Human (*Homo sapiens*)	GCA_000001305.2	Genome Reference Consortium Human GRCh38

(MEGA) (*Kumar, Stecher & Tamura, 2016*), the evolutionary relationship between the CYP450 genes of the horse and the corresponding gene sequences of the other species were inferred. Furthermore, a phylogenetic tree was constructed depicting the evolutionary relationship between the cytochrome P450 enzymes of the horse and the matching gene sequences of the selected species.

A detailed description on how to build a phylogenetic tree from molecular data with MEGA is given by *Hall (2013)*. Briefly, the sequence alignment was performed using Multiple Sequence Comparison by Log Expectation (*Edgar, 2004*). Subsequently, different substitution models were assessed for the goodness of fit measured by the Bayesian information criterion (BIC) (*Schwarz, 1978*). Based on the lowest BIC value, the Kimura 2-parameter model (*Kimura, 1980*) (CYP2E1, CYP3A89, CYP3A96) and the Tamura 3-parameter model (*Tamura, 1992*) (CYP11A1, CYP17A1, CYP19A1, CYP27B1, CYP2A13, CYP2C113, CYP2C92, CYP2D50, CYP3A93, CYP3A94, CYP3A95, CYP3A97) were chosen to assess the evolutionary distance based on the Maximum Likelihood method. The initial trees for the heuristic search were constructed automatically. Therefore, the Neighbor-Join and BioNJ algorithms were applied to a matrix of pairwise distances, which were estimated using a maximum composite likelihood approach. The topology with the best log likelihood value was chosen. Additionally, in order to model the evolutionary rate differences amongst sites (five categories), a discrete gamma distribution was applied (*Yang, 1994*). Codon positions included were 1st + 2nd + 3rd + Noncoding. Positions with less than 95% site coverage were eliminated.

The bootstrap consensus tree based on 1,000 replicates (*Felsenstein, 1985*) was built in order to assess the reliability of a phylogenetic tree. The percentage of the recovery of the same nodes throughout the bootstrap analysis is indicated next to the branches. The analysis was based on nine nucleotide sequences from the different species. Another bootstrap consensus tree (1,000 replicates) of all equine CYP450s and the matching gene sequences of the chosen species was computed and displayed in the circular view. The estimation of the evolutionary tree was based on the Maximum Likelihood

Figure 1 Molecular phylogenetic relationship of CYP11A1 (A), CYP17A1 (B), CYP19A1 (C), CYP27B1 (D), CYP2A13 (E), CYP2C113 (F), CYP2C92 (G), CYP2D50 (H) and CYP2E1 (I) across nine different species.

method. It includes 135 nucleotide sequences from nine different species and was constructed using the Tamura-3-parameter model. Branches corresponding to partitions reproduced in less than 50% bootstrap replicates were collapsed. The initial trees for the heuristic search were constructed automatically. Therefore, the Neighbor-Join and BioNJ algorithms were applied to a matrix of pairwise distances, which were estimated using a maximum composite likelihood approach. The topology with the best log likelihood value was chosen. In order to model the evolutionary rate differences amongst sites (five categories, parameter = 1.8250), a discrete gamma distribution was applied (*Yang, 1994*). The rate variation model allowed for some sites to be evolutionary invariable (2.6181% sites). Codon positions included were 1st + 2nd + 3rd + Noncoding. All positions with less than 95% site coverage were eliminated.

Furthermore, the evolutionary distance between the nucleotide sequences of the equine CYP3A enzymes and the matching gene sequences of the white rhino and of the other species were computed using the pairwise distance function in MEGA (*Kumar, Stecher & Tamura, 2016*). The nucleotide differences between each pair of sequences were calculated to facilitate the assessment of the degree of similarity among the sequences.

RESULTS

The individual phylogenetic trees for each P450 enzyme detected in the horse (CYP11A1, CYP17A1, CYP19A1, CYP27B1, CYP2A13, CYP2C113, CYP2C92, CYP2D50, CYP2E1, CYP3A89, CYP3A93, CYP3A94, CYP3A95, CYP3A96 and CYP3A97) are depicted in Figs. 1 and 2. The phylogenetic trees highlight the evolutionary relationship of the equine

Figure 2 Molecular phylogenetic relationship of the CYP3A89 (A), CYP3A93 (B), CYP3A94 (C), CYP3A95 (D), CYP3A96 (E) and CYP3A97 (F) across nine different species by Maximum Likelihood (ML) method.

Table 2 Degree of similarity (%) between the equine CYP450 genes and the genome sequences of the white rhinoceros.

CYP450 of the horse	Similarity (%) to the genome sequences of the white rhinoceros and the horse
CYP11A1 (NM_001082521)	89.8
CYP17A1 (NM_001082523)	91
CYP19A1 (NM_001081805)	89
CYP27B1 (NM_001163957)	94.1
CYP2A13 (NM_001111337)	91.3
CYP2C113 (NM_001291302)	90.7
CYP2C92 (NM_001101652)	87.8
CYP2D50 (NM_001111306)	92.4
CYP2E1 (NM_001111303)	91.2
CYP3A89 (NM_001101651)	90.6
CYP3A93 (NM_001190938)	91.7
CYP3A94 (NM_001190939)	93
CYP3A95 (NM_001190940)	90.5
CYP3A96 (NM_001146163)	89.2
CYP3A97 (NM_001146164)	88.8

gene sequences and the gene sequences of the white rhino, the cow, the dog, the pig, the elephant, the sheep, the mouse and the human. In all cases, the alignment of the CYP genes of the horse with the gene sequences of the other species showed that the horse CYP enzymes are most closely related to the sequences of the white rhino. The degree of similarity between the known equine CYP450 genes and the sequences identified in the genome of the white rhino ranged from 87.8% to 94.1% (Table 2). On average, the white rhino nucleotide sequences were 90.74% identical to the equine CYP450 gene

Figure 3 Circular phylogenetic tree depicting the relationship of 135 nucleotide sequences of all CYP450 genes of the horse and the matched nucleotide sequences of eight other species (also named CYP450).

sequences. Figure 3 illustrates the relationship between all CYP450 genes of the horse and the matching nucleotide sequences of the other species (also named CYP450s in the phylogenetic trees). Gene sequences of all CYP enzyme families identified in the horse seem to be present in the white rhino.

Table 3 Estimates of evolutionary divergence between the nucleotide sequences of the white rhino, which matched the equine CYP3A sequences.

	CYP3A89_rhino	CYP3A93_rhino	CYP3A94_rhino	CYP3A95_rhino	CYP3A96_rhino	CYP3A97_rhino
CYP3A89_rhino						
CYP3A93_rhino	0.066					
CYP3A94_rhino	0.056	0.059				
CYP3A95_rhino	0.059	0.023	0.036			
CYP3A96_rhino	0.000	0.066	0.056	0.059		
CYP3A97_rhino	0.056	0.056	0.043	0.046	0.056	

Notes:
Presented as numbers of base differences per site between each pair of sequences. Codon positions included were 1st + 2nd + 3rd + Noncoding. Evolutionary analyses were conducted in MEGA (*Kumar, Stecher & Tamura, 2016*).

The calculation of the pairwise distance between the nucleotide sequences of the rhino (Table 3) revealed that the CYP3A gene sequences were identical or highly similar with distance indexes of as little as 0.023 between the CYP3A95 and the CYP3A93 nucleotide sequence and 0 between the CYP3A96 and CYP3A89 nucleotide sequences. Further investigations showed that the sequences matching all the equine CYP3A genes were found at the same location in the genome of the rhino and overlapped each other in most cases. Additionally, the calculation of the pairwise distance of the CYP3A nucleotide sequences of the cow, dog, pig, human and sheep matched to the equine CYP3A sequences demonstrate a very high degree of similarity of up to 100% identity amongst each other (S1).

DISCUSSION

While large numbers of different species, diseases and conditions require medical attention and treatment, wildlife veterinarians are often faced with the lack of approved and scientifically evaluated drugs for zoo and wildlife species. A study published by *Tana et al. (2010)* stated that only 8–10 compounds are approved for the use in zoo and wildlife in the USA in contrast to close to 300 in cattle. The white rhino represents one of the species where basic medical knowledge is not yet readily available. However, the poaching crisis and the increasing numbers of injured individuals requiring urgent medical help has been on the rise, especially for the treatment of wounds. To overcome limitations in species specific information, the medical management of the rhino tends to be based on information available for the horse. However, the findings of a recent study we undertook in rhinos showed that the half-life of elimination for carprofen was more than threefold longer than that in the horse (*Leiberich et al., 2018*). This made us question the validity of the horse as a model.

The differences in drug metabolism could generally arise from distinctions in anatomy, physiology, behaviour, biotransformation and metabolism by CYP450 enzymes. While these potential influencing factors can all be considered, we believe that with the horse and the rhino showing a closely related digestive physiology and anatomy of the gastrointestinal tract and similar feeding habits, the differences in drug metabolism would most likely be ascribed to distinctions in their CYP450 enzymes. To assess this

assumption, the gene sequences of the CYP450s of the horse, the white rhino and other selected species were compared as a first step in ascertaining if any of the genes coding for the major drug metabolising families were absent in the rhino genome. From the gene analysis it would appear that the complete genetic deletion of a major CYP enzyme family was not the cause of the evident limitations in drug metabolism, leaving functional differences in enzymes activity as the likely reason. The latter was evident in the subsequent relatedness analysis. While showing the horse to be the most closely related species, only 90.74% similarity were evident across all the equine CYP enzymes. This finding would indicate that the genetic differences between the horse and the rhino are sufficient to result in major differences in drug metabolism. This would render drug prediction between the species unreliable at the clinical level.

Similar conclusions have been previously drawn by *Fink-Gremmels (2008)*, *Martignoni, Groothuis & De Kanter (2006)*, *Nelson, Goldstone & Stegeman (2013)* and *Toutain, Ferran & Bousquet-Mélou (2010)* who declared that small differences in the amino acid sequence of the CYP enzyme can lead to marked changes in substrate specificity and catalytic activity. Thus, not even closely related species with similar physiological characteristics exhibit similar cytochrome P450 enzyme activity. Even a single change in amino acid sequences is sufficient to possibly alter substrate specificity (*Lindberg & Negishi, 1989*) and different CYP450 enzymes may metabolise the same substrate (*Guengerich, 1997*). In more serious cases, the genetic difference could result in stop codons being present in the incorrect area within the mRNA sequence with abnormal termination of the enzyme translation (*McAdam, Goundis & Reid, 1988*). Contrary to general expectations, the enzyme liver pattern of herbivore and carnivore species, of monogastric species and ruminants and even within a species such as cattle, differs markedly (*Fink-Gremmels, 2008*). *Guengerich (1997)* suggested a provisional classification according to 'catalytic preservation' of the CYP450 enzymes. Accordingly, the only CYP450 enzyme, which can be accurately extrapolated across species is the CYP2E1. The extrapolation of the CYP1A1, 1A2 and 17A enzymes needs to be conducted carefully. Even more caution is required for the extrapolation of CYP2D and 3A, whereas the extrapolation of CYP2A, 2B and 2C enzymes across species shows no catalytic preservation.

Another important finding in this study relates to the CYP3A enzyme family. In humans, it represents about 30% of the total liver CYP content and metabolises around 50% of all marketed drugs. Its most important drug metaboling isoenzyme is the CYP3A4 (*Furge & Guengerich, 2006*). While detailed information on the importance of the different isoenzymes and their contribution to drug metabolism in animals is not yet available, one would assume that the important drug metabolising CYP families are the same as in humans. The importance of these enzymes is further evident by the number of isoenzymes within the group. Four have been identified in man (CYP3A4, 3A5, 3A7 and 3A43) and six in the horse (CYP3A89, CYP3A93, CYP3A94, CYP3A95, CYP3A96, CYP3A97), with the equine CYP3A89 exhibiting the highest similarity to the human CYP3A4 (*Schmitz et al., 2010*).

The pairwise distance analysis between the CYP3A nucleotide sequences of the white rhino revealed high levels of similarity (Table 3). Additionally, the nucleotide sequences were all limited to the same location (JH767858: 353657–1001765) in the genome of the rhino. This finding suggests that the CYP3A family in the rhino genome has no isoenzymes, and consequently, that the white rhino has fewer isoenzymes than the horse. Overall, with the CYP3A subfamily being of major importance for the drug metabolism, a lack of isoenzymes may explain the observed constraint in white rhino. However, similar observations were made based on the pairwise comparison of the CYP3A gene sequences in the other species. In most cases, the sequences of the pig, cow, dog, human and sheep, which were matched to the different CYP3A gene sequences of the horse did not reveal any sequence difference and thus seemed to represent one single nucleotide sequence as in the rhino (S1). Alternatively, those findings may imply that the white rhino, like other species may have its own, species specific set of drug metabolising CYP3A isoenzymes, which differ from those in the horse. Rather than reflecting a true non-existence of CYP3A isoenzymes, those may have just not yet been identified in the rhino.

Similar to the rhino, drug doses for elephants, another species belonging to the hindgut fermenters, are often extrapolated from pharmacokinetic data available for horses (*Hunter, Isaza & Koch, 2003*; *Mortenson, 2001*). However, the comparison of the CYP3A gene sequences also showed that unlike in the rhino, the elephants' CYP3A gene sequences seem to be the closest to those of the mouse and not closest related to the horse nor to the white rhino (Fig. 2). This finding may further indicate that drug dose extrapolation from horses to other hindgut fermenters and mega-herbivores such as the elephant needs to be conducted with caution and cannot be based solely on the fact that they share similar physiological characteristics.

CONCLUSION

In conclusion, the rhino as a species was not overly deficient for any of the genes coding for the major metabolizing enzymes. While the white rhino CYP450 gene sequences were most similar to those of the horse, this was overall only at the 90% level. Despite appearing to be a minor distinction, even smaller differences are known to have a major effect on drug metabolism. As a result, despite the close anatomical relationship, the rhino should not simply be treated like a big horse.

ACKNOWLEDGEMENTS

The authors thank Dr. Emmanuel Adawaren for his introduction to the program MEGA and Dr. Micheal Hewetson for editing the manuscript.

Funding

The University of Pretoria provided financial support in the form of a bursary for Marion Leiberich, a Ph.D. candidate. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
The University of Pretoria provided financial support in the form of a bursary for
Marion Leiberich, a Ph.D. candidate.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Marion Leiberich conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
- Hendrik Johannes Marais contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.
- Vinny Naidoo conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, authored or reviewed drafts of the paper, approved the final draft.

Data Availability

The raw data are provided in a Supplemental File.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/
peerj.5718#supplemental-information.

REFERENCES

Anzenbacher P, Anzenbacherova E. 2001. Cytochromes P450 and metabolism of xenobiotics. *Cellular and Molecular Life Sciences* **58(5–6)**:737–747.

Archibald AL, Bolund L, Churcher C, Fredholm M, Groenen MAM, Harlizius B, Lee K-T, Milan D, Rogers J, Rothschild MF, Uenishi H, Wang J, Schook LB, Swine Genome Sequencing Consortium. 2010a. Pig genome sequence—analysis and publication strategy. *BMC Genomics* **11(1)**:438 DOI 10.1186/1471-2164-11-438.

Archibald AL, Cockett NE, Dalrymple BP, Faraut T, Kijas JW, Maddox JF, McEwan JC, Oddy VH, Raadsma HW, Wade C, Wang J, Wang W, Xun X, The International Sheep Genomics Consortium. 2010b. The sheep genome reference sequence: a work in progress. *Animal Genetics* **41(5)**:449–453 DOI 10.1111/j.1365-2052.2010.02100.x.

Edgar RC. 2004. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. *BMC Bioinformatics* **5**:113 DOI 10.1186/1471-2105-5-113.

Emslie RH, Milliken T, Talukdar B, Ellis S, Keryn A, Knight MH. 2016. African and Asian Rhinoceroses—status, conservation and trade. A report from the IUCN Species Survival Commission (IUCN SSC) African and Asian Rhino Specialist Groups and TRAFFIC to the CITES Secretariat pursuant to Resolution Conf. 9.14 (Rev. CoP15).

Estabrook RW. 2003. A passion for P450s (remembrances of the early history of research on cytochrome P450). *Drug Metabolism and Disposition* **31(12)**:1461–1473 DOI 10.1124/dmd.31.12.1461.

Felsenstein J. 1985. Confidence-limits on phylogenies—an approach using the bootstrap. *Evolution* **39(4)**:783–791 DOI 10.2307/2408678.

Fink-Gremmels J. 2008. Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. *European Journal of Pharmacology* **585(2–3)**:502–509 DOI 10.1016/j.ejphar.2008.03.013.

Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. 1999. Cytochrome P4502C is an EDHF synthase in coronary arteries. *Nature* **401(6752)**:493–497 DOI 10.1038/46816.

Furge LL, Guengerich FP. 2006. Cytochrome P450 enzymes in drug metabolism and chemical toxicology. *Biochemistry and Molecular Biology Education* **34(2)**:66–74 DOI 10.1002/bmb.2006.49403402066.

Guengerich FP. 1997. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. *Chemico-Biological Interactions* **106(3)**:161–182 DOI 10.1016/s0009-2797(97)00068-9.

Hall BG. 2013. Building phylogenetic trees from molecular data with MEGA. *Molecular Biology and Evolution* **30(5)**:1229–1235 DOI 10.1093/molbev/mst012.

Hunter RP, Isaza R, Koch DE. 2003. Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus). *American Journal of Veterinary Research* **64(1)**:109–114 DOI 10.2460/ajvr.2003.64.109.

Ioannides C. 2006. Cytochrome P450 expression in the liver of food-producing animals. *Current Drug Metabolism* **7(4)**:335–348 DOI 10.2174/138920006776873544.

Jiang Y, Xie M, Chen W, Talbot R, Maddox JF, Faraut T, Wu C, Muzny DM, Li Y, Zhang W, Stanton J, Brauning R, Barris WC, Hourlier T, Aken BL, Searle SMJ, Adelson DL, Bian C, Cam GR, Chen Y, Cheng S, DeSilva U, Dixen K, Dong Y, Fan G, Franklin IR, Fu S, Fuentes-Utrilla P, Guan R, Highland MA, Holder ME, Huang G, Ingham AB, Jhangiani SN, Kalra D, Kovar CL, Lee SL, Liu W, Liu X, Lu C, Lv T, Mathew T, McWilliam S, Menzies M, Pan S, Robelin D, Servin B, Townley D, Wang W, Wei B, White SN, Yang X, Ye C, Yue Y, Zeng P, Zhou Q, Hansen JB, Kristiansen K, Gibbs RA, Flicek P, Warkup CC, Jones HE, Oddy VH, Nicholas FW, McEwan JC, Kijas JW, Wang J, Worley KC, Archibald AL, Cockett N, Xu X, Wang W, Dalrymple BP. 2014. The sheep genome illuminates biology of the rumen and lipid metabolism. *Science* **344(6188)**:1168–1173 DOI 10.1126/science.1252806.

Kent WJ. 2002. BLAT—the BLAST-like alignment tool. *Genome Research* **12(4)**:656–664 DOI 10.1101/gr.229202.

Kimura M. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide-sequences. *Journal of Molecular Evolution* **16(2)**:111–120 DOI 10.1007/bf01731581.

Klingenberg M. 1958. Pigments of rat liver microsomes. *Archives of Biochemistry and Biophysics* **75(2)**:376–386 DOI 10.1016/0003-9861(58)90436-3.

Kumar S, Stecher G, Tamura K. 2016. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. *Molecular Biology and Evolution* **33(7)**:1870–1874 DOI 10.1093/molbev/msw054.

Leiberich M, Krebber R, Hewetson M, Marais J, Naidoo V. 2018. A study of the pharmacokinetics and thromboxane inhibitory activity of a single intramuscular dose of carprofen as a means to establish its potential use as an analgesic drug in white rhinoceros. *Journal of Veterinary Pharmacology and Therapeutics* **41(4)**:605–613 DOI 10.1111/jvp.12508.

Lindberg RLP, Negishi M. 1989. Alteration of mouse cytochrome-P450coh substrate-specificity by mutation of a single amino-acid residue. *Nature* **339(6226)**:632–634 DOI 10.1038/339632a0.

Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, Zody MC, Mauceli E, Xie XH, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, DeJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly MJ, DeCaprio D, Gnerre S, Grabherr M, Kellis M, Kleber M, Bardeleben C, Goodstadt L, Heger A, Hitte C, Kim L, Koepfli KP, Parker HG, Pollinger JP, Searle SMJ, Sutter NB, Thomas R, Webber C, Lander ES, Broad Inst Genome Sequencing Plat. 2005. Genome sequence, comparative analysis and haplotype structure of the domestic dog. *Nature* **438(7069)**:803–819 DOI 10.1038/nature04338.

Martignoni M, Groothuis GMM, De Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. *Expert Opinion on Drug Metabolism & Toxicology* **2(6)**:875–894 DOI 10.1517/17425255.2.6.875.

McAdam RA, Goundis D, Reid KBM. 1988. A homozygous point mutation results in a stop codon in the C1q B-chain of a C1q-deficient individual. *Immunogenetics* **27(4)**:259–264 DOI 10.1007/bf00376120.

Mortenson J. 2001. Determining dosages for antibiotic and anti-inflammatory agents. In: Csuti B, Sargent EL, Bechert US, eds. *The Elephant's Foot: Prevention and Care of Foot Conditions in Captive Asian and African Elephants.* Ames: Iowa State University Press, 144.

Nebert DW, Russell DW. 2002. Clinical importance of the cytochromes P450. *The Lancet* **360(9340)**:1155–1162 DOI 10.1016/s0140-6736(02)11203-7.

Nelson DR. 2006. Cytochrome P450 nomenclature, 2004. *Methods in Molecular Biology* **320**:1–10 DOI 10.1385/1-59259-998-2:1.

Nelson DR, Goldstone JV, Stegeman JJ. 2013. The cytochrome P450 genesis locus: the origin and evolution of animal cytochrome P450s. *Philosophical Transactions of the Royal Society B: Biological Sciences* **368(1612)**:20120474.

Payne A, Hales D. 2004. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. *Endocrine Reviews* **25(6)**:947–970 DOI 10.1210/er.2003-0030.

Poaching Statistics. 2018. *Save the Rhino International. Available at* https://www.savetherhino.org/rhino_info/poaching_statistics.

Schmitz A, Demmel S, Peters LM, Leeb T, Mevissen M, Haase B. 2010. Comparative human-horse sequence analysis of the CYP3A subfamily gene cluster. *Animal Genetics* **41**:72–79 DOI 10.1111/j.1365-2052.2010.02111.x.

Schwarz G. 1978. Estimating the dimension of a model. *Annals of Statistics* **6(2)**:461–464 DOI 10.1214/aos/1176344136.

Smith HS. 2009. Opioid metabolism. *Mayo Clinic Proceedings* **84(7)**:613–624 DOI 10.4065/84.7.613.

Tamura K. 1992. Estimation of the number of nucleotide substitutions when there are strong transition-transversion and G+c-content biases. *Molecular Biology and Evolution* **9(4)**:678–687 DOI 10.1093/oxfordjournals.molbev.a040752.

Tana LM, Isaza R, Koch DE, Hunter RP. 2010. Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus). *Journal of Zoo and Wildlife Medicine* **41(3)**:418–425 DOI 10.1638/2009-0073.1.

Tougard C, Delefosse T, Hanni C, Montgelard C. 2001. Phylogenetic relationships of the five extant rhinoceros species (Rhinocerotidae, Perissodactyla) based on mitochondrial

cytochrome b and 12S rRNA genes. *Molecular Phylogenetics and Evolution* **19(1)**:34–44 DOI 10.1006/mpev.2000.0903.

Toutain P, Ferran A, Bousquet-Mélou A. 2010. Species differences in pharmacokinetics and pharmacodynamics. *Comparative and Veterinary Pharmacology* **199**:19–48.

Uenishi H, Morozumi T, Toki D, Eguchi-Ogawa T, Rund LA, Schook LB. 2012. Large-scale sequencing based on full-length-enriched cDNA libraries in pigs: contribution to annotation of the pig genome draft sequence. *BMC Genomics* **13(1)**:581 DOI 10.1186/1471-2164-13-581.

Van Der Weide J, Hinrichs JWJ. 2006. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. *Clinical Biochemist Reviews* **27(1)**:17–25.

Wade CM, Giulotto E, Sigurdsson S, Zoli M, Gnerre S, Imsland F, Lear TL, Adelson DL, Bailey E, Bellone RR, Blöcker H, Distl O, Edgar RC, Garber M, Leeb T, Mauceli E, MacLeod JN, Penedo MCT, Raison JM, Sharpe T, Vogel J, Andersson L, Antczak DF, Biagi T, Binns MM, Chowdhary BP, Coleman SJ, Della Valle G, Fryc S, Guerin G, Hasegawa T, Hill EW, Jurka J, Kiialainen A, Lindgren G, Liu J, Magnani E, Mickelson JR, Murray J, Nergadze SG, Onofrio R, Pedroni S, Piras MF, Raudsepp T, Rocchi M, Røed KH, Ryder OA, Searle S, Skow L, Swinburne JE, Syvänen AC, Tozaki T, Valberg SJ, Vaudin M, White JR, Zody MC, Lander ES, Lindblad-Toh K, Broad Institute Genome Sequencing Platform, Broad Institute Whole Genome Assembly Team. 2009. Genome sequence, comparative analysis, and population genetics of the domestic horse. *Science* **326(5954)**:865–867 DOI 10.1126/science.1178158.

Yang ZH. 1994. Maximum-likelihood phylogenetic estimation from DNA-sequences with variable rates over sites—approximate methods. *Journal of Molecular Evolution* **39(3)**:306–314 DOI 10.1007/bf00160154.

Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacology & Therapeutics* **138(1)**:103–141 DOI 10.1016/j.pharmthera.2012.12.007.

Zimin AV, Delcher AL, Florea L, Kelley DR, Schatz MC, Puiu D, Hanrahan F, Pertea G, Van Tassell CP, Sonstegard TS, Marçais G, Roberts M, Subramanian P, Yorke JA, Salzberg SL. 2009. A whole-genome assembly of the domestic cow, Bos taurus. *Genome Biology* **10(4)**:R42 DOI 10.1186/gb-2009-10-4-r42.